Results 1 to 10 of about 20,731 (163)
Molecules, 2022 Aztreonam is a Gram-negative bacteria-targeting synthetic monobactam antibiotic. Human serum albumin (HSA) plays an important role in the transference of pharmaceuticals, hormones, and fatty acids, along with other compounds, determining their ...
Altaf Khan, Khan Altaf
exaly +3 more sources
Antibiotics, 2021 Infections caused by metallo-β-lactamase (MBL)-producing Enterobacterales and Pseudomonas are increasingly reported worldwide and are usually associated with high mortality rates (>30%).
Alberto Enrico Maraolo +2 more
exaly +3 more sources
Comparative analysis of the effects of aztreonam combined with four β-lactamase inhibitors against carbapenem-resistant Enterobacterales [PDF]
Microbiology SpectrumCarbapenem-resistant Enterobacterales (CRE) pose a global public health threat due to multidrug resistance and treatment failure. This study evaluated the effects of aztreonam combined with four β-lactamase inhibitors (avibactam, clavulanic acid ...
Qing Meng +9 more
doaj +2 more sources
High in vitro activity of aztreonam/avibactam against NDM-producing Enterobacterales with emerging resistance in Escherichia coli in the United States Mid-Atlantic region [PDF]
Microbiology SpectrumNew Delhi metallo-β-lactamase (NDM)-producing Enterobacterales represent a critical antimicrobial resistance threat with limited therapeutic options. Aztreonam/avibactam, which combines the stability of aztreonam against metallo-β-lactamases with the ...
Eetu Eklund +11 more
doaj +2 more sources
Antibiotics, 2023 Background: Despite the availability of new options (ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam and cefiderocol), it is still very difficult to treat infections caused by metallo-β-lactamase (MBLs)-producers resistant to aztreonam.
Cécile Emeraud +2 more
doaj +1 more source
Aztreonam: clinical and pharmacological characteristics at the present stage [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2023 One of the urgent problems of modern health care is the growing resistance of microorganisms to antibiotics, including carbapenems, which until recently were considered as the drugs of choice in the treatment of life-threatening infections.
Popov D.A. +2 more
doaj +1 more source
Direct Detection of Extended Spectrum β-Lactamases from Positive Blood Cultures by using Aztreonam and Clavulanate [PDF]
Journal of Clinical and Diagnostic Research, 2021 Introduction: Bacterial Sepsis by Multidrug Resistant Gram Negative Bacilli (MDRGNB) producing Extended Spectrum β-Lactamases (ESBL) is one of the major causes of mortality and morbidity in hospitals.
Renji Francis +3 more
doaj +1 more source
Microbiology Spectrum, 2021 Aztreonam-avibactam is under clinical development for multidrug-resistant Gram-negative infections. We evaluated in vitro activity against 341 recent clinical isolates.
David R. Snydman, Laura McDermott
doaj +1 more source
Antimicrobial therapy of sepsis caused by carbapenem-resistant Klebsiella pneumoniae in patients with hematological malignancies [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2022 Objective. To compare the efficacy of ceftazidime-avibactam and aztreonam combination therapy with “standard” therapy in patients with hematological malignancies and sepsis, caused by carbapenemresistant K. pneumoniae. Materials and Methods.
Barantsevich N.E., Barantsevich E.P.
doaj +1 more source
Microbiology Spectrum, 2021 Ceftazidime-avibactam (CZA) has emerged as a promising solution to the lack of new antibiotics against Pseudomonas aeruginosa infections. Data from in vitro assays of CZA combinations, however, are scarce. The objective of our study was to perform a time-
María M. Montero +12 more
doaj +1 more source